MNG447
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.448
- E2F_TARGETS+0.429
- MYC_TARGETS_V2+0.421
- MYC_TARGETS_V1+0.387
- WNT_BETA_CATENIN_SIGNALING+0.386
- HEDGEHOG_SIGNALING+0.354
- UNFOLDED_PROTEIN_RESPONSE+0.343
- MITOTIC_SPINDLE+0.295
- CHOLESTEROL_HOMEOSTASIS+0.259
- ANGIOGENESIS+0.242
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.465
- INTERFERON_GAMMA_RESPONSE-0.462
- ALLOGRAFT_REJECTION-0.396
- INFLAMMATORY_RESPONSE-0.371
- TNFA_SIGNALING_VIA_NFKB-0.349
- IL6_JAK_STAT3_SIGNALING-0.300
- COMPLEMENT-0.221
- KRAS_SIGNALING_UP-0.209
- APOPTOSIS-0.181
- COAGULATION-0.173
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.879 |
| 2 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.875 |
| 3 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.872 |
| 4 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.871 |
| 5 | C3N-04155 | — | cohortSQ2 | 0.863 |
| 6 | TCGA-21-5786-01A-01R-1635-07 | — | cohortSQ1 | 0.862 |
| 7 | BS_DS438CXE | high-grade glioma | — | 0.858 |
| 8 | MNG1194 | — | — | 0.857 |
| 9 | SRR8613740 | — | E | 0.857 |
| 10 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.448 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.429 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.421 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.387 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.386 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.354 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.343 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.259 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.242 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.214 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.211 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.127 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.111 | Idelalisib | — uncovered |
| PEROXISOME | 0.108 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.084 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.072 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.069 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.057 | Inavolisib | — uncovered |